巴瑞替尼单药治疗中重度特应性皮炎:两项随机III期试验
两项独立、多中心、双盲、III期单药试验(BREEZE-AD1和BREEZE-AD2)纳入对局部治疗应答不佳的中重度特应性皮炎成人患者,随机接受安慰剂或巴瑞替尼1mg、2mg、4mg每日一次治疗16周。结果显示巴瑞替尼4mg和2mg组达到主要终点(vIGA-AD 0或1)的患者比例显著高于安慰剂,且瘙痒在治疗第1周(4mg)或第2周(2mg)即改善,安全性与此前研究一致。
要点
- 巴瑞替尼4mg和2mg每日一次治疗16周可显著改善中重度AD的体征和症状。
- 瘙痒改善迅速,4mg组第1周、2mg组第2周即观察到显著效果。
- 最常见不良事件为鼻咽炎和头痛,未观察到新安全性信号。
核心结论
- 巴瑞替尼4mg和2mg单药治疗16周可显著改善对局部治疗应答不佳的中重度特应性皮炎患者的临床体征和症状,并快速减轻瘙痒。
研究设计与样本
- 两项独立、多中心、双盲、III期单药试验(BREEZE-AD1和BREEZE-AD2),成人中重度特应性皮炎患者按2:1:1:1随机接受安慰剂或巴瑞替尼1mg、2mg、4mg每日一次治疗16周。
- BREEZE-AD1纳入624例患者,BREEZE-AD2纳入615例患者。
主要发现
- 巴瑞替尼治疗患者最常见不良事件为鼻咽炎和头痛;未观察到心血管事件、静脉血栓栓塞、胃肠道穿孔、显著血液学变化或死亡。
临床怎么用
- 对于对局部皮质类固醇应答不佳的中重度特应性皮炎成人患者,巴瑞替尼4mg或2mg每日一次可作为单药治疗选择,需关注16周内的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. OBJECTIVES: To evaluate the efficacy and safety of baricitinib in patients with moderate-to-severe AD who had an inadequate response to topical therapies. METHODS: In two independent, multicentre, double-blind, phase III monotherapy trials, BREEZE-AD1 and BREEZE-AD2, adults with moderate-to-severe AD were randomized 2 : 1 : 1 : 1 to once-daily placebo, baricitinib 1 mg, 2 mg, or 4 mg for 16 weeks. RESULTS: At week 16, more patients achieved the primary end point of Validated Investigator's Global Assessment of AD (0, 1) on baricitinib 4 mg and 2 mg compared with placebo in BREEZE-AD1 [N = 624; baricitinib 4 mg 16·8% (P < 0·001), 2 mg 11·4% (P < 0·05), 1 mg 11·8% (P < 0·05), placebo 4·8%], and BREEZE-AD2 [N = 615; baricitinib 4 mg 13·8% (P = 0·001), 2 mg 10·6% (P < 0·05), 1 mg 8·8% (P = 0·085), placebo 4·5%]. Improvement in itch was achieved as early as week 1 for 4 mg and week 2 for 2 mg. Improvements in night-time awakenings, skin pain and quality-of-life measures were observed by week 1 for both 4 mg and 2 mg (P ≤ 0·05, all comparisons). The most common adverse events in patients treated with baricitinib were nasopharyngitis and headache. No cardiovascular events, venous thromboembolism, gastrointestinal perforation, significant haematological changes, or death were observed with any baricitinib dosage. CONCLUSIONS: Baricitinib improved clinical signs and symptoms in patients with moderate-to-severe AD within 16 weeks of treatment and induced rapid reduction of itch. The safety profile remained consistent with prior findings from baricitinib clinical development in AD, with no new safety concerns.
引用
- Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020. PMID: 31995838. doi:10.1111/bjd.18898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。